Pfizer says its coronavirus vaccine is more than 90 percent effective

The better-than-expected result is the first Phase III data from any of the four candidates now in the final stage of testing in the U.S.

Pfizer says its coronavirus vaccine is more than 90 percent effective

WASHINGTON — A coronavirus vaccine developed by Pfizer is more than 90 percent effective, according to the first look at data from a late-stage U.S. trial involving nearly 44,000 participants.

An analysis of 94 trial participants who contracted COVID-19 showed that the vaccine was 94 percent effective, the company and its partner BioNTech said in a press release Monday.

The pair added that they expect to apply to the FDA for an emergency-use authorization before the end of the month, after they have collected sufficient data on the vaccine’s safety.

The better-than-expected result is the first Phase III data from any of the four candidates now in the final stage of testing in the U.S.